Literature DB >> 8907102

Decline in self-reported dysphoria after treatment entry in inner-city cocaine addicts.

S D Husband1, D B Marlowe, R J Lamb, M Y Iguchi, D A Bux, K C Kirby, J J Platt.   

Abstract

This study examined self-reported dysphoria in 82 consecutive admissions to intensive outpatient treatment for cocaine abuse on whom data for the Beck scales for depression, anxiety, and hopelessness were available for intake and 4 subsequent weeks with no more than 1 missing data point. Mean scores on the Beck Depression Inventory (BDI) and the Beck Anxiety Inventory (BAI) decreased significantly between intake and Week 1, with no further significant changes from Weeks 1-4. Similar drops in the rate of clinically significant BDI and BAI scores also were observed. Scores on the Beck Hopelessness Scale (BHS) showed no significant changes. By Week 4, rates of clinically significant depression, anxiety, and hopelessness were similar (17%, 13%, and 16%, respectively). These findings suggest that assessing depression and anxiety using the BDI and BAI in this population should be postponed for at least 1 week after intake and that intake levels of self-reported mood may be inappropriate baseline measures for evaluating treatment effects.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8907102     DOI: 10.1037//0022-006x.64.1.221

Source DB:  PubMed          Journal:  J Consult Clin Psychol        ISSN: 0022-006X


  12 in total

1.  Treating depression and substance use: a randomized controlled trial.

Authors:  Sarah B Hunter; Katherine E Watkins; Kimberly A Hepner; Susan M Paddock; Brett A Ewing; Karen C Osilla; Suzanne Perry
Journal:  J Subst Abuse Treat       Date:  2012-02-01

2.  Psychosocial treatments for cocaine dependence: the role of depressive symptoms.

Authors:  Niklaus Stulz; Michael E Thase; Robert Gallop; Paul Crits-Christoph
Journal:  Drug Alcohol Depend       Date:  2011-03-01       Impact factor: 4.492

3.  Sertraline delays relapse in recently abstinent cocaine-dependent patients with depressive symptoms.

Authors:  Alison Oliveto; James Poling; Michael J Mancino; D Keith Williams; Jeff Thostenson; Rhonda Pruzinsky; Kishorchandra Gonsai; Mehmet Sofuoglu; Gerardo Gonzalez; Shanti Tripathi; Thomas R Kosten
Journal:  Addiction       Date:  2011-10-10       Impact factor: 6.526

Review 4.  On beyond urine: clinically useful assessment instruments in the treatment of drug dependence.

Authors:  K M Carroll; B J Rounsaville
Journal:  Behav Res Ther       Date:  2002-11

5.  Suicide attempts within 12 months of treatment for substance use disorders.

Authors:  Peter C Britton; Kenneth R Conner
Journal:  Suicide Life Threat Behav       Date:  2010-02

6.  Changes in PTSD symptomatology during acute and protracted alcohol and cocaine abstinence.

Authors:  Scott F Coffey; Julie A Schumacher; Kathleen T Brady; Bonnie Dansky Cotton
Journal:  Drug Alcohol Depend       Date:  2006-09-27       Impact factor: 4.492

7.  Psychometric assessment of a self-administered version of the Significant Other Survey.

Authors:  Lois A Benishek; Meridith Carter; Nicolle T Clements; Cassandra Allen; Kristin E Salber; Karen L Dugosh; Kimberly C Kirby
Journal:  Psychol Addict Behav       Date:  2012-10-15

8.  A comparison of two depressive symptomatology measures in residential substance abuse treatment clients.

Authors:  Kimberly A Hepner; Sarah B Hunter; Maria O Edelen; Annie J Zhou; Katherine Watkins
Journal:  J Subst Abuse Treat       Date:  2009-04-08

9.  Meta-analysis of depression and substance use and impairment among cocaine users.

Authors:  Kenneth R Conner; Martin Pinquart; Amanda P Holbrook
Journal:  Drug Alcohol Depend       Date:  2008-06-27       Impact factor: 4.492

10.  Depression among methamphetamine users: association with outcomes from the Methamphetamine Treatment Project at 3-year follow-up.

Authors:  Suzette Glasner-Edwards; Patricia Marinelli-Casey; Maureen Hillhouse; Alfonso Ang; Larissa J Mooney; Richard Rawson
Journal:  J Nerv Ment Dis       Date:  2009-04       Impact factor: 2.254

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.